{"id":7993,"date":"2025-06-23T12:45:07","date_gmt":"2025-06-23T12:45:07","guid":{"rendered":"https:\/\/www.europesays.com\/us\/7993\/"},"modified":"2025-06-23T12:45:07","modified_gmt":"2025-06-23T12:45:07","slug":"galatea-bio-launches-revolutionary-genetic-testing-platform-for-major-diseases","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/7993\/","title":{"rendered":"Galatea Bio Launches Revolutionary Genetic Testing Platform for Major Diseases"},"content":{"rendered":"

MIAMI & OAKLAND, Calif.–(BUSINESS WIRE)–
\nGalatea Bio<\/a> and Fabric Genomics<\/a>, a GeneDx<\/a> company, announced today a strategic collaboration to enhance genetic testing by incorporating both rare pathogenic variant analysis and polygenic risk scoring (PRS) to assess genetic susceptibility to common diseases.<\/p>\n

\nThe initial offering will include an inherited cardiovascular gene panel based on American Heart Association (AHA) recommendations, with additional PRS for cardiovascular related traits, including coronary arterial disease, high low-density lipoprotein (LDL), elevated triglycerides, low high-density lipoprotein (HDL), atrial fibrillation, hypertension, type 2 diabetes and hypothyroidism. A follow-up offering will integrate hereditary cancer panels with PRS for breast, colorectal, and prostate cancers.<\/p>\n

\n\u201cGalatea Bio is committed to making common genetic risk prediction more accurate for all,\u201d said Carlos Bustamante, Ph.D., CEO & Co-Founder, Galatea Bio. \u201cThrough our collaboration with Fabric Genomics, we\u2019re working to capture both rare and common genetic contributions to disease risk\u2014delivering meaningful insights to individuals across the US and around the world.\u201d<\/p>\n

\nThis collaboration integrates Fabric Genomics\u2019 platform for clinical reporting and its expertise in clinical gene panel curation with Galatea Bio\u2019s advanced PRS algorithms. By combining these capabilities, the partnership provides both rare variant and polygenic genetic risk reporting using the Broad Clinical Lab\u2019s (BCL) Blended Genome – Exome. A key component of this collaboration is the integration of Galatea Bio\u2019s newly released individually-adjusted PRS solution, StrataRisk\u2122 PRS, which provides genetic risk for individuals of all ancestries. This is made possible through a novel, proprietary algorithm that leverages data from the Galatea Bio Global Biobank to calibrate PRS scores against similar individuals in genomic ancestry space, ensuring equitable risk assessment across diverse populations.<\/p>\n

\n\u201cBy leveraging Fabric Genomics\u2019 high-quality clinical gene panel interpretation to support Galatea\u2019s polygenic risk score reporting, we are enabling more personalized assessments of an individual\u2019s risk for common diseases,\u201d said Martin Reese, Ph.D., President of Fabric Genomics. \u201cThis combined approach allows us to better explain patients\u2019 results with a more accurate risk profile.\u201d<\/p>\n

\nEvaluating both rare genetic disease variants and polygenic risk scores can have several advantages over reporting either of these independently. Traditional single-gene or multi-gene panel testing focuses on high-penetrance rare mutations, which capture a subset of patients with an inherited single gene disease and often results in negative or uncertain results, leaving many patients’ risk unexplained. PRS, which aggregates the cumulative effect of numerous common genetic variants, can provide refined risk stratification.<\/p>\n

\n\u201cThis collaboration between Fabric Genomics and Galatea Bio is enabled by our clinical Blended Genome – Exome,\u201d said Niall Lennon, Ph.D., Chief Scientific Officer, Broad Clinical Labs. \u201cThis is exactly the kind of application we envisioned for this cost-effective approach\u2014one that will provide a more comprehensive view of genetic susceptibility to important common diseases.\u201d<\/p>\n

\nAbout Fabric Genomics<\/b><\/p>\n

\nFabric Genomics, a GeneDx company, is democratizing genomics-driven precision medicine. The company provides institutions with end-to-end clinical sequencing solutions that include the Fabric Enterprise software platform, assay design and validation support and the clinical interpretation services needed to scale genetic testing. At the core of this platform is a suite of sophisticated AI algorithms and data knowledge systems that turn data into expert clinical insights. Headquartered in Oakland, California, Fabric Genomics supports clinical applications across a variety of use cases including rare disease, oncology, cardiovascular, neurological and women\u2019s health. To learn more, visit fabricgenomics.com<\/a> and follow us on X<\/a> and LinkedIn<\/a>.<\/p>\n

\nAbout GeneDx<\/b><\/p>\n

\nAt GeneDx (Nasdaq: WGS<\/a>), we believe that everyone deserves personalized, targeted medical care\u2014and that it all begins with a genetic diagnosis. Fueled by one of the world\u2019s largest, rare disease data sets, our industry-leading exome and genome tests translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery and improve health system efficiencies. For more information, please visit genedx.com<\/a> and connect with us on LinkedIn<\/a>, Facebook<\/a> and Instagram<\/a>.<\/p>\n

\nAbout Galatea Bio<\/b><\/p>\n

\nGalatea Bio is an innovative, venture-backed biotechnology company that strives to advance ‘Precision Health at Scale for All.’ Founded by pioneers in the fields of population genetics and bioinformatics, Galatea Bio leverages cutting-edge ancestry algorithms to scale the promise of precision health to global populations, while maintaining a strong commitment to ethical research. The company is headquartered in Miami Lakes, Florida. For more information, visit www.galatea.bio<\/a> or follow us on X<\/a> and LinkedIn<\/a>.<\/p>\n

\nAbout the Broad Clinical Labs<\/b><\/p>\n

\nBroad Clinical Laboratories was founded in 2013 as a non-profit subsidiary of Broad Institute of MIT and Harvard to accelerate the world toward a better understanding, diagnosis and treatment of disease by pursuing projects, developing products and driving adoption of cutting edge genomics technologies and novel molecular assays. Broad Clinical Labs is a leader in translational genomics, having sequenced over 700,000 genomes in service of its mission to accelerate the understanding and diagnosis of human disease. www.broadclinicallabs.org<\/a><\/p>\n

\nForward Looking Statements<\/b><\/p>\n

\nThis press release may contain \u201cforward-looking statements\u201d within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words \u201cbelieve,\u201d \u201cproject,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201cestimate,\u201d \u201cintend,\u201d \u201cstrategy,\u201d \u201cfuture,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cmay,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cwould,\u201d \u201cwill be,\u201d \u201cwill continue,\u201d \u201cwill likely result,\u201d and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) our ability to implement business combinations, plans, goals and forecasts, and identify and realize additional opportunities, (ii) the risk of downturns and a changing regulatory landscape in the highly competitive healthcare industry, (iii) the size and growth of the market in which we operate, (iv) our ability to pursue our new strategic direction, and (v) our ability to enhance our artificial intelligence tools that we use in our clinical interpretation platform. The foregoing list of factors is not exhaustive. A further list and description of risks, uncertainties and other matters can be found in the \u201cRisk Factors\u201d section of our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and other documents filed by us from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and we assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. We do not give any assurance that we will achieve our expectations.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: https:\/\/www.businesswire.com\/news\/home\/20250623728878\/en\/<\/a><\/p>\n

\nGalatea Contact:
\n<\/b>
info@galatea.bio
\n<\/a>
Fabric Genomics Contact:
\n<\/b>
Press@GeneDx.com<\/a><\/p>\n

Source: GeneDx<\/p>\n